

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of the claims in the application:

Listing of Claims:

Claims 1 - 17 (cancelled)

Claim 18: (currently amended): An isolated linear peptide obtained from an antibiotic peptide ~~or a moiety of said linear peptide to vectorize active substances, said moiety of said linear peptide being made up of at least five successive amino acids of SEQ. ID NO: 23,~~ wherein said isolated peptide is devoid of a disulphide bond and wherein said isolated peptide comprises the sequence: Arg-Arg-Leu-Ser-Tyr-Ser-Arg-Arg-Arg-Phe (SEQ ID NO: 23).

Claim 19: (previously presented): The isolated linear peptide of claim 18, wherein the antibiotic peptide is a  $\beta$ -stranded antibiotic peptide.

Claim 20: (currently amended): A method for vectoring an active substance using a linear peptide having a sequence of which if SEQ. ID NO. ~~:23 or a moiety of said linear peptide to vectorize active substances, said moiety of said linear peptide being made up of at least five successive amino acids of SEQ. ID. NO. 23~~, wherein said active substance is selected from the group consisting of peptides, polypeptides, antibodies, nucleic acids, oligonucleotides and chemical molecules, and said linear peptide ~~or said moiety of said linear peptide made up of at least five successive amino acids~~

of SEQ. ID NO. 23 is devoid of disulphide bonds, said disulphide bonds being removed, replaced by another amino acid or wherein one or more cysteines in said peptide ~~or said moiety of said linear peptide made up of at least five successive amino acids of SEQ. ID No. 23~~ is blocked at the SH group level, said method comprising the steps of:

(a) coupling said active substance to said linear peptide ~~or to said moiety of said linear peptide made up of at least five successive amino acids of SEQ. ID No. 23~~; and

(b) conveying said active substances coupled with said linear peptide ~~or with said moiety of said linear peptide made up of at least five successive amino acids of SEQ. ID No. 23~~ to a target for vectoring, said target being selected from the group consisting of a particular cell compartment, a particular cell type, and a particular organ.

Claims 21 - 23. (cancelled)

Claim 24: (currently amended): A method of vectoring an active substance selected from the group consisting of peptides, polypeptides, antibodies, nucleic acids, oligonucleotides and chemical molecules using a linear peptide according to claim 18, the method comprising the steps of:

(a) coupling said active substance to said linear peptide; and

(b) conveying said active substance coupled with said linear peptide to a target for vectoring, said target being selected from the group consisting of a particular cell compartment, a particular cell type and a particular organ.

Claims 25 - 28. (cancelled)

Claim 29: (currently amended) : A compound of formula (IV) :

$$\underbrace{(\text{Y})_n}_{\text{wherein}} - (\text{A}) - \text{Z}_m$$

wherein:

A is a peptide according to claim 18;

Z represents an active substance selected from the group consisting of peptides, polypeptides, antibodies, nucleic acids, oligonucleotides and chemical molecules;

~~Y represents a signal agent selected from the group consisting of oligopeptides, proteins, antibodies and chemical ligands, said signal agent having an affinity towards a particular cell type, cell compartment or a specific tissue or organ, or the ability to recognize a specific determinant present on a particular cell type, cell compartment or a specific tissue or organ,~~

~~N is 0 or 1,~~

~~m is 1 to 10.~~

Claim 30: (currently amended) : The compound according to claim 25 37, wherein at least one of the active substances (Z) is attached by a covalent bond to either the N-terminal or C-terminal ends ~~or at the primary amino groups carried by the side chains of the lysines of linear peptide (A)~~.

Claims 31 - 32. (cancelled)

Claim 33: (currently amended) A pharmaceutical composition comprising as active ingredient at least one compound of formula (IV) according to claim 37, optionally associated with an acceptable vehicle or carrier.

Claim 34: (previously presented): A diagnostic agent comprising at least one compound of formula (IV) according to claim 37.

Claims 35 - 36. (cancelled)

Claim 37: (currently amended) A compound of the formula (IV) :

$(Y)_n - (A) - Z_m$

wherein:

A represents a linear peptide having a sequence of which is SEQ. ID NO: 23 ~~or a moiety of said linear peptide made up of at least five successive amino acids of SEQ. ID NO. 23;~~

Z represents an active substance selected from the group consisting of ~~peptides~~, polypeptides, antibodies, nucleic acids, oligonucleotides and chemical molecules;

~~Y represents a signal agent selected from the group consisting of oligopeptides, proteins, antibodies and chemical ligands, said signal agent having an affinity towards a particular cell type, cell compartment or a specific tissue or organ, or the ability to recognize a specific determinant present on a~~

~~particular cell type, cell compartment or a specific tissue or organ;~~

~~N is 0 or 1;~~

~~m is 1 to 10.~~

38. (currently amended) A compound according to claim 37 wherein said chemical molecules are selected from the group consisting of anti-tumorals, antivirals, ~~anti-inflammatories, and antibacterials agents preventing the degradation of organs and/or tissues.~~